eli lilly tirzepatide shortage US judge sides with FDA's removal of Lilly's weight loss drug from list FDA confirms end of Eli

however, new technologies like chemical modifications (e.g., cyclic peptides), nanoparticles, and specific absorption enhancers (like SNAC in Ozempic's oral version, Rybelsus) are making oral delivery possible for certain therapeutic peptides, like semaglutide (Wegovy/Ozempic), transforming them from injections to convenient tablets, though many supplements lack strong evidence

Fluoroquinolone exposure tends to suppress the TCA cycle and activate the glyoxylate shunt, conserving carbon and reducing ROS while channeling electrons into NADPH/GSH synthesis

Tirzepatide takes weight loss therapies to the next level by targeting both GLP-1 and GIP receptors

Together, these studies allowed us to evaluate tirzepatides therapeutic potential while beginning to characterize what biological mechanisms might account for any observed effects